Syngene targets supplying 500,000 Remdesivir vials in India amid COVID-19 surge
Syngene, majority owned by biopharmaceutical company Biocon Ltd, is one of the seven Indian companies that have licensed remdesivir from U.S.-based Gilead Sciences Inc27-05-2021